Targeting the sphingolipid signaling pathway in stroke.
Pfeilschifter
Waltraud
W
Czech
Bozena
B
Neumann-Haefelin
Tobias
T
D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D002986:Clinical Trials as Topic; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011409:Propylene Glycols / Q000627:therapeutic use*; D051381:Rats; D049349:Receptors, Lysosphingolipid / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000502:physiology*; D013107:Sphingolipids / Q000378:metabolism*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; D013107:Sphingolipids; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine